HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple‐negative breast cancer

MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer

(2020) Jessica C. Casciano et al.   BRITISH JOURNAL OF CANCER

HRD1 prevents atherosclerosis-mediated endothelial cell apoptosis by promoting LOX-1 degradation

(2020) Qingguo Li et al.   CELL CYCLE

Metabolic Reprogramming in Triple-Negative Breast Cancer

(2020) Xiangyu Sun et al.   Frontiers in Oncology

Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition–resistant triple-negative breast cancer cells

(2019) Larissa Menezes dos Reis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

(2019) Robert D. Leone et al.   SCIENCE

Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis

(2018) Anna Halama et al.   CANCER LETTERS

ER-associated ubiquitin ligase HRD1 programs liver metabolism by targeting multiple metabolic enzymes

(2018) Juncheng Wei et al.   Nature Communications

Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity

(2018) Zhao Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation

(2017) Heather J. Wright et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Metabolic Interactions in the Tumor Microenvironment

(2017) Costas A. Lyssiotis et al.   TRENDS IN CELL BIOLOGY

HRD1 prevents apoptosis in renal tubular epithelial cells by mediating eIF2α ubiquitylation and degradation

(2017) Yujie Huang et al.   Cell Death & Disease

Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition

(2017) Michael Lampa et al.   PLoS One

The Emerging Hallmarks of Cancer Metabolism

(2016) Natalya N. Pavlova et al.   Cell Metabolism

Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation

(2016) Min Pan et al.   NATURE CELL BIOLOGY

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer

(2016) Roman Camarda et al.   NATURE MEDICINE

Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer

(2016) Q Qu et al.   Cell Death & Disease

Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer

(2016) Jun Hyoung Park et al.   Cell Reports

Amino Acid Transporters in Cancer and Their Relevance to "Glutamine Addiction": Novel Targets for the Design of a New Class of Anticancer Drugs

(2015) Y. D. Bhutia et al.   CANCER RESEARCH

The E3 ligase synoviolin controls body weight and mitochondrial biogenesis through negative regulation of PGC-1 

(2015) H. Fujita et al.   EMBO JOURNAL

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis

(2015) Yan Xiang et al.   JOURNAL OF CLINICAL INVESTIGATION

Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis

(2014) T. Wu et al.   GENES & DEVELOPMENT

Hrd1-mediated BLIMP-1 ubiquitination promotes dendritic cell MHCII expression for CD4 T cell priming during inflammation

(2014) Heeyoung Yang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ubiquitin Ligases in Cholesterol Metabolism

(2014) Wei Jiang et al.   Diabetes & Metabolism Journal

Defining human ERAD networks through an integrative mapping strategy

(2011) John C. Christianson et al.   NATURE CELL BIOLOGY

Glutamine addiction: a new therapeutic target in cancer

(2010) David R. Wise et al.   TRENDS IN BIOCHEMICAL SCIENCES

Triple-negative breast cancer--current status and future directions

(2009) O. Gluz et al.   ANNALS OF ONCOLOGY